000 06416cam a2200853Mi 4500
005 20250919085811.0
006 m o d u
007 cr |||||||||||
008 161221s2015 ne o 001 0 eng d
020 _a9780128002247
_qelectronic bk.
020 _a0128002247
_qelectronic bk.
020 _z9780128002063
020 _z0128002069
029 0 _aNLGGC
_b394179072
029 1 _aCHVBK
_b33870972X
029 1 _aCHBIS
_b010491482
029 1 _aCHVBK
_b338085742
029 1 _aCHDSB
_b006420722
029 1 _aCHVBK
_b341786853
029 1 _aCHBIS
_b010548004
029 1 _aDEBSZ
_b451527356
029 1 _aGBVCP
_b832501999
035 _a(OCoLC)913208366
_z(OCoLC)913695384
035 _a(OCoLC)ocn913208366
039 9 _y12-21-2016
_zhafiz
_wmetacoll.MYUKM.updates.D20160920.T210208.sdallbooks.1 (perolehan)hafizupload21122016.mrc
_x190
040 _aNLGGC
_beng
_erda
_epn
_cNLGGC
_dNST
_dOPELS
_dNST
_dYDXCP
_dEBLCP
_dCOO
_dIDEBK
_dCDX
_dDEBSZ
_dOCLCF
049 _aMAIN
050 4 _aRC271.G45
072 7 _aMED
_x014000
_2bisacsh
072 7 _aMED
_x022000
_2bisacsh
072 7 _aMED
_x112000
_2bisacsh
072 7 _aMED
_x045000
_2bisacsh
082 0 4 _a616.99/40695
_223
245 0 0 _aEpigenetic cancer therapy /
_cedited by Steven G. Gray.
264 1 _aAmsterdam :
_bElsevier :
_bAcademic Press,
_c[2015]
264 4 _cò015
300 _a1 online resource (xxvi, 721 pages)
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
490 0 _aTranslational Epigenetics Series
500 _aIncludes index.
500 _aAcademic Press is an imprint of Elsevier.
504 _aIncludes bibliographical references at the end of each chapters and index.
505 0 _aFront Cover; Epigenetic Cancer Therapy; Copyright Page; Contents; List of Contributors; 1 Introduction; 1 Introduction to the Area (Key Concepts); 2 Epigenetics and Cancer; 3 Targeting Aberrant Epigenetics; 4 Issues to Overcome/Areas of Concern; 5 Future Directions: Translation to the Clinic; References; 1 Introduction and Key Concepts; 2 DNA Methylation and Hydroxymethylation in Cancer; 1 Introduction; 2 Epigenetics; 2.1 Chromatin Structure; 2.2 DNA Methylation in Cellular Homeostasis; 2.2.1 Genomic distribution of DNA methylation; 2.2.2 Functional role of DNA methylation
505 8 _a2.2.3 DNA methyltransferases2.2.4 Recruitment of DNMTs; 2.3 DNA Demethylation; 3 DNA Methylation Patterns in Cancer; 3.1 Hypermethylation in Cancer; 3.2 Hypomethylation in Cancer; 3.3 Methods for 5mC Detection; 4 Aberrations of Enzymes Involved in DNA Methylation Homeostasis in Cancer; 4.1 DNA Methyltransferase; 4.2 TET Proteins; 4.3 Isocitrate Dehydrogenases; 4.4 Succinate Dehydrogenases; 5 DNA Hydroxymethylation in Cancer; 5.1 Methods for 5hmC Detection; 5.1.1 Affinity-based enrichment approach; 5.1.2 Chemical methods; 5.1.3 Quantitative methods at single base resolution
505 8 _a5.1.4 Third-generation sequencing5.2 DNA Hydroxymethylation Patterns in Cancer; 6 Conclusion; References; 3 Writers, Readers, and Erasers of Epigenetic Marks; 1 Introduction; 2 Writers; 2.1 DNA Methyltransferases; 2.2 Histone Lysine Methyltransferases; 2.3 Protein Arginine Methyltransferases; 2.4 Histone Acetyltransferases; 3 Readers; 3.1 Methyl-CpG-Binding Proteins; 3.2 Histone Methylation-Binding Domains; 3.3 Histone Acetylation-Binding Domains; 4 Erasers; 4.1 Proteins Involved in DNA Demethylation; 4.2 Histone Demethylases; 4.3 Histone Deacetylases (HDACs)
505 8 _a5 Interactions between the Various Components6 Epigenetics and Cancer; 6.1 DNA Methylation and Cancer; 6.2 Histone Methylation and Cancer; 6.3 Histone Acetylation and Cancer; 7 Epigenetic Proteins as Therapeutic Targets; 8 Conclusion and Future Opportunities; References; 4 MicroRNAs and Cancer; 1 miRNA Biogenesis and Functionality; 2 miRNAs in Cancer Biology; 3 miRNA: An Epigenetic Perspective; 3.1 Epigenetic Alteration of miRNA Expression; 3.2 Epi-miRNA; 3.3 miRNA with Epigenetic Functions; 4 miRNA Epigenetic Therapy; 4.1 miRNA Inhibition in Cancer; 4.2 miRNA Replacement in Cancer
505 8 _a4.3 Small-Molecule-Based miRNA Modulation5 Future Perspectives; Acknowledgments; References; 5 Long Noncoding RNAs and Cancer; 1 Introduction; 2 Classification and Nomenclature of lncRNAs; 2.1 Classification; 2.2 Nomenclature; 3 Mechanisms of lncRNA Function; 3.1 lncRNAs as Decoys and Guides; 3.2 lncRNAs as Scaffolds; 3.3 lncRNAs as Signaling Molecules; 3.4 miRNA Sequestration; 3.5 lncRNAs and Epigenetic Regulation; 3.5.1 H19; 3.5.2 AIR and KCNQ1OT1; 3.5.3 lincRNAs; 4 lncRNAs and Human Disease; 4.1 Prognostic Markers; 4.1.1 lncRNAs in the circulation
520 _aEpigenetic Cancer Therapy unites issues central to a translational audience actively seeking to understand the topic. It is ideal for cancer specialists, including oncologists and clinicians, but also provides valuable information for researchers, academics, students, governments, and decision-makers in the healthcare sector. The text covers the basic background of the epigenome, aberrant epigenetics, and its potential as a target for cancer therapy, and includes individual chapters on the state of epigenome knowledge in specific cancers (including lung, breast, prostate, liver). The bo.
590 _aElsevier
_bScienceDirect All Books
650 0 _aCancer
_xGene therapy.
650 0 _aEpigenetics.
650 7 _aMEDICAL / Clinical Medicine
_2bisacsh
650 7 _aMEDICAL / Diseases
_2bisacsh
650 7 _aMEDICAL / Evidence-Based Medicine
_2bisacsh
650 7 _aMEDICAL / Internal Medicine
_2bisacsh
650 4 _aCancer -- Treatment.
650 4 _aCancer.
650 4 _aMedicine.
650 7 _aCancer
_xGene therapy.
_2fast
_0(OCoLC)fst00845367
650 7 _aEpigenetics.
_2fast
_0(OCoLC)fst01893642
655 4 _aElectronic books.
655 0 _aElectronic books.
700 1 _aGray, Steven G.,
_eeditor.
776 0 8 _iPrint version:
_aGray, Steven
_tEpigenetic Cancer Therapy
_dBurlington : Elsevier Science,c2015
_z9780128002063
856 4 0 _uhttps://eresourcesptsl.ukm.remotexs.co/user/login?url=http://www.sciencedirect.com/science/book/9780128002063
907 _a.b16401086
_b2022-11-02
_c2019-11-12
942 _n0
914 _avtls003614213
998 _ae
_b2016-08-12
_cm
_dz
_feng
_gne
_y0
_z.b16401086
999 _c613494
_d613494